StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
366A.T$1059.00-3.46%
Fair $1059.00+0.0%

366A.T

366A.T

Healthcare / Health Information ServicesTokyo

$1059.00

-38.00 (-3.46%)

Fairly Valued+0.0%Fair Value $1059.00Fund rank 34/100 · Data gapFallback financials|
SA 61/B
F-Score: 7/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 25% · confianza 25%

FCF escenarios

weak_data · normalized FCF $553.2M · quality 66.0/100

Data gap 34/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 56/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

61/100

B

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

12/100

SEC 0%

Latest source: unknownPeriods: 3Warnings: 0unknown: 3
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 366A.TLocal privado en este navegador · 366A.T
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$13.2B

P/E

15.7x

↓

EV/EBITDA

6.4x

↓

ROE

22.5%

↑

Gross Margin

20.0%

↓

Debt/Equity

0.00

↓
52-Week Range$1059
$899$2060

TradingView lightweight chart

366A.T price, volumen y niveles de valoración

Último $1,059Periodo -42.1%
Fair value: $1,059

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2023–2025 · 2 años de histórico normalizado

Revenue CAGR

+14.4%

FCF CAGR

+60.0%

FCF margin

10.1%

FCF / Net income

1.82x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $14.06B · net income $776.2M · FCF $1.42B

2023-FY → 2025-FY

Gross margin

20.0%-0.9% pts

Operating margin

7.9%+0.2% pts

Net margin

5.5%+0.3% pts

FCF margin

10.1%+4.9% pts
MetricTTM
2025
2024
2023
Income Statement
Revenue$14.06B$14.06B$13.27B$10.75B
Net Income$776.2M$776.2M$680.4M$560.3M
EBITDA$1.36B$1.36B$1.18B$1.02B
EPS71.2371.2362.4446.70
Gross Margin20.0%20.0%19.4%20.9%
Operating Margin7.9%7.9%7.3%7.7%
Net Margin5.5%5.5%5.1%5.2%
Balance Sheet
Debt/Equity0.000.000.000.00
Current Ratio2.252.25——
Cash Flow
Free Cash Flow$1.42B$1.42B$129.7M$553.2M
Returns
ROE22.5%22.5%23.6%23.7%
Valuation
P/E15.7215.72——
EV/EBITDA6.446.44——
P/B3.343.34——
Growth & Yield
Revenue Growth6.0%6.0%23.4%—
EPS Growth14.1%14.1%33.7%—
Dividend Yield7.6%7.6%——

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

9.7%

razonable

EPS terminal req.

$93.97

Spread vs growth

4.4%

5Y implied EPS CAGR

9.8%

razonable

EPS terminal req.

$113.70

Spread vs growth

4.3%

10Y implied EPS CAGR

9.9%

razonable

EPS terminal req.

$183.12

Spread vs growth

4.2%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total -34.6%

Total return

-34.6%

Start / end P/E

29.3x → 14.9x

EPS bridge

62.44 → 71.23

Residual

-6.9%

EPS growth+14.1%
Multiple rerating-49.3%
Dividend+7.6%
Residual / FX / buybacks / cross-term-6.9%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.